Vickers A J, Smith C
Memorial Sloan-Kettering Cancer Center, Integrative Medicine Service, 1275 York Avenue, New York, NY 10021, USA.
Cochrane Database Syst Rev. 2006 Jul 19(3):CD001957. doi: 10.1002/14651858.CD001957.pub3.
Influenza is a highly infectious viral disease that is particularly common in the winter months. Oscillococcinum is a patented, commercially available homoeopathic medicine. The rationale for its use in influenza comes from the homoeopathic principle of 'let like be cured by like'. This medicine is manufactured from wild duck heart and liver, which are said to be reservoirs for influenza viruses.
To determine whether homoeopathic Oscillococcinum or similar medicines are more effective than placebo in the prevention and treatment of influenza and influenza-like syndromes.
We updated the electronic searches on the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006); MEDLINE (January 1966 to February 2006) and EMBASE (1980 to February 2006). The manufacturers of Oscillococcinum were contacted for information.
Placebo-controlled trials of Oscillococcinum or homeopathically-prepared influenza virus, influenza vaccine or avian liver in the prevention and treatment of influenza and influenza-like syndromes.
Two authors extracted data and assessed methodological quality independently.
Seven studies were included in the review, three prevention trials (number of participants (n) = 2265) and four treatment trials (n = 1194). Only two studies reported sufficient information to complete data extraction fully. There was no evidence that homoeopathic treatment can prevent influenza-like syndrome (relative risk (RR) 0.64, 95% confidence interval (CI) 0.28 to 1.43). Oscillococcinum treatment reduced the length of influenza illness by 0.28 days (95% CI 0.50 to 0.06). Oscillococcinum also increased the chances that a patient considered treatment to be effective (RR 1.08; 95% CI 1.17 to 1.00).
AUTHORS' CONCLUSIONS: Though promising, the data were not strong enough to make a general recommendation to use Oscillococcinum for first-line treatment of influenza and influenza-like syndromes. Further research is warranted but the required sample sizes are large. Current evidence does not support a preventative effect of Oscillococcinum-like homeopathic medicines in influenza and influenza-like syndromes.
流感是一种极具传染性的病毒性疾病,在冬季尤为常见。奥司他韦是一种获得专利的、可在市场上买到的顺势疗法药物。其用于治疗流感的理论依据来自顺势疗法的“以毒攻毒”原则。这种药物由野鸭的心脏和肝脏制成,据说这些器官是流感病毒的储存宿主。
确定顺势疗法的奥司他韦或类似药物在预防和治疗流感及流感样综合征方面是否比安慰剂更有效。
我们更新了对Cochrane对照试验中心注册库(CENTRAL)(《Cochrane图书馆》2006年第1期)、MEDLINE(1966年1月至2006年2月)和EMBASE(1980年至2006年2月)的电子检索。我们联系了奥司他韦的制造商以获取信息。
关于奥司他韦或顺势疗法制备的流感病毒、流感疫苗或禽类肝脏在预防和治疗流感及流感样综合征方面的安慰剂对照试验。
两位作者独立提取数据并评估方法学质量。
该综述纳入了7项研究,3项预防试验(参与者人数(n)=2265)和4项治疗试验(n = 1194)。只有两项研究报告了足够信息以完全完成数据提取。没有证据表明顺势疗法治疗可预防流感样综合征(相对危险度(RR)0.64,95%置信区间(CI)0.28至1.43)。奥司他韦治疗使流感病程缩短了0.28天(95%CI 0.50至0.06)。奥司他韦还增加了患者认为治疗有效的可能性(RR 1.08;95%CI 1.17至1.00)。
尽管有前景,但数据不够有力,无法做出使用奥司他韦作为流感和流感样综合征一线治疗药物的一般性推荐。需要进一步研究,但所需样本量很大。目前的证据不支持奥司他韦类顺势疗法药物在流感和流感样综合征中的预防作用。